Kamunting Street Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Kamunting Street Capital Management’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-75,000	Closed	-$117K	–	36
2022 Q3	$117K	Buy	+75,000	New	+$124K	0.19%	28
2022 Q1	–	Sell	-64,539	Closed	-$189K	–	53
2021 Q4	$189K	Buy	+64,539	New	+$139K	0.14%	40
2021 Q2	–	Sell	-42,594	Closed	-$163K	–	73
2021 Q1	$192K	Sell	42,594 -1,239	-3%	-$6.68K	0.08%	87
2020 Q4	$216K	Sell	43,833 -56,167	-56%	-$281K	0.11%	80
2020 Q3	$593K	Buy	+100,000	New	+$400K	0.37%	33

Other funds holding XERS

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Kamunting Street Capital Management's XERS Position: Q4 2022 in Review

Kamunting Street Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q4 2022, closing a stake of 75,000 shares — an estimated $117K sold.

Kamunting Street Capital Management first reported a position in XERS in Q3 2020 and held it in 5 quarters. The position peaked at $593K in Q3 2020. 97 funds tracked by Wall St. Rank hold XERS as of Q4 2022.

Kamunting Street Capital Management reported no remaining Xeris Biopharma Holdings position as of Q4 2022 after selling out during the quarter.
Kamunting Street Capital Management sold 75,000 Xeris Biopharma Holdings shares in Q4 2022, an estimated $117K.
Kamunting Street Capital Management first reported a position in Xeris Biopharma Holdings in Q3 2020 and held it in 5 quarters.
Kamunting Street Capital Management's Xeris Biopharma Holdings position peaked at $593K in Q3 2020.
97 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2022.

Based on Kamunting Street Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.